Lactoferrin for prevention of neonatal infections

Paolo Manzoni, Michael Mostert, Mauro Stronati

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Purpose of review: Sepsis-related morbidity and mortality is an increasing concern in all neonatal ICUs (NICUs). Sepsis occurs in 20-40% of all preterm patients, and although much is known on the origin, the incidence is reported to be constantly increasing. Many risk factors account for the increased risk of sepsis in preterms, including use of broad-spectrum antibiotics selecting resistant microflora and pathogenic gut colonization, parenteral nutrition, acid inhibitors and steroids, as well as the systematic and long-lasting use of invasive management and in-dwelling lines. As treatment does not prevent severe long-term neurodevelopmental impairment and sequelae in septic premature neonates, the best strategy is to avoid infections rather than to treat them. Recent findings: Published results from several recent randomized controlled trials currently show a level I evidence that fluconazole for prevention of fungal sepsis, probiotics for prevention of necrotizing enterocolitis, and bovine lactoferrin for prevention of bacterial sepsis should be considered as preventive strategies in NICUs. Summary: In this article, the current evidence in favour of lactoferrin use in preterm neonates will be reviewed and the areas of further research and future improvements will be discussed in order to illustrate the implications of the recent findings for clinical practice or research.

Original languageEnglish
Pages (from-to)177-182
Number of pages6
JournalCurrent Opinion in Infectious Diseases
Volume24
Issue number3
DOIs
Publication statusPublished - Jun 2011

Fingerprint

Lactoferrin
Sepsis
Infection
Neonatal Intensive Care Units
Newborn Infant
Necrotizing Enterocolitis
Fluconazole
Parenteral Nutrition
Probiotics
Research
Randomized Controlled Trials
Steroids
Anti-Bacterial Agents
Morbidity
Acids
Mortality
Incidence

Keywords

  • bovine lactoferrin
  • infection
  • neonate
  • preterm
  • prevention
  • sepsis

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Lactoferrin for prevention of neonatal infections. / Manzoni, Paolo; Mostert, Michael; Stronati, Mauro.

In: Current Opinion in Infectious Diseases, Vol. 24, No. 3, 06.2011, p. 177-182.

Research output: Contribution to journalArticle

Manzoni, Paolo ; Mostert, Michael ; Stronati, Mauro. / Lactoferrin for prevention of neonatal infections. In: Current Opinion in Infectious Diseases. 2011 ; Vol. 24, No. 3. pp. 177-182.
@article{625619e955f8425f8384e1ad0e658b31,
title = "Lactoferrin for prevention of neonatal infections",
abstract = "Purpose of review: Sepsis-related morbidity and mortality is an increasing concern in all neonatal ICUs (NICUs). Sepsis occurs in 20-40{\%} of all preterm patients, and although much is known on the origin, the incidence is reported to be constantly increasing. Many risk factors account for the increased risk of sepsis in preterms, including use of broad-spectrum antibiotics selecting resistant microflora and pathogenic gut colonization, parenteral nutrition, acid inhibitors and steroids, as well as the systematic and long-lasting use of invasive management and in-dwelling lines. As treatment does not prevent severe long-term neurodevelopmental impairment and sequelae in septic premature neonates, the best strategy is to avoid infections rather than to treat them. Recent findings: Published results from several recent randomized controlled trials currently show a level I evidence that fluconazole for prevention of fungal sepsis, probiotics for prevention of necrotizing enterocolitis, and bovine lactoferrin for prevention of bacterial sepsis should be considered as preventive strategies in NICUs. Summary: In this article, the current evidence in favour of lactoferrin use in preterm neonates will be reviewed and the areas of further research and future improvements will be discussed in order to illustrate the implications of the recent findings for clinical practice or research.",
keywords = "bovine lactoferrin, infection, neonate, preterm, prevention, sepsis",
author = "Paolo Manzoni and Michael Mostert and Mauro Stronati",
year = "2011",
month = "6",
doi = "10.1097/QCO.0b013e32834592e6",
language = "English",
volume = "24",
pages = "177--182",
journal = "Current Opinion in Infectious Diseases",
issn = "0951-7375",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Lactoferrin for prevention of neonatal infections

AU - Manzoni, Paolo

AU - Mostert, Michael

AU - Stronati, Mauro

PY - 2011/6

Y1 - 2011/6

N2 - Purpose of review: Sepsis-related morbidity and mortality is an increasing concern in all neonatal ICUs (NICUs). Sepsis occurs in 20-40% of all preterm patients, and although much is known on the origin, the incidence is reported to be constantly increasing. Many risk factors account for the increased risk of sepsis in preterms, including use of broad-spectrum antibiotics selecting resistant microflora and pathogenic gut colonization, parenteral nutrition, acid inhibitors and steroids, as well as the systematic and long-lasting use of invasive management and in-dwelling lines. As treatment does not prevent severe long-term neurodevelopmental impairment and sequelae in septic premature neonates, the best strategy is to avoid infections rather than to treat them. Recent findings: Published results from several recent randomized controlled trials currently show a level I evidence that fluconazole for prevention of fungal sepsis, probiotics for prevention of necrotizing enterocolitis, and bovine lactoferrin for prevention of bacterial sepsis should be considered as preventive strategies in NICUs. Summary: In this article, the current evidence in favour of lactoferrin use in preterm neonates will be reviewed and the areas of further research and future improvements will be discussed in order to illustrate the implications of the recent findings for clinical practice or research.

AB - Purpose of review: Sepsis-related morbidity and mortality is an increasing concern in all neonatal ICUs (NICUs). Sepsis occurs in 20-40% of all preterm patients, and although much is known on the origin, the incidence is reported to be constantly increasing. Many risk factors account for the increased risk of sepsis in preterms, including use of broad-spectrum antibiotics selecting resistant microflora and pathogenic gut colonization, parenteral nutrition, acid inhibitors and steroids, as well as the systematic and long-lasting use of invasive management and in-dwelling lines. As treatment does not prevent severe long-term neurodevelopmental impairment and sequelae in septic premature neonates, the best strategy is to avoid infections rather than to treat them. Recent findings: Published results from several recent randomized controlled trials currently show a level I evidence that fluconazole for prevention of fungal sepsis, probiotics for prevention of necrotizing enterocolitis, and bovine lactoferrin for prevention of bacterial sepsis should be considered as preventive strategies in NICUs. Summary: In this article, the current evidence in favour of lactoferrin use in preterm neonates will be reviewed and the areas of further research and future improvements will be discussed in order to illustrate the implications of the recent findings for clinical practice or research.

KW - bovine lactoferrin

KW - infection

KW - neonate

KW - preterm

KW - prevention

KW - sepsis

UR - http://www.scopus.com/inward/record.url?scp=79955523889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955523889&partnerID=8YFLogxK

U2 - 10.1097/QCO.0b013e32834592e6

DO - 10.1097/QCO.0b013e32834592e6

M3 - Article

C2 - 21415742

AN - SCOPUS:79955523889

VL - 24

SP - 177

EP - 182

JO - Current Opinion in Infectious Diseases

JF - Current Opinion in Infectious Diseases

SN - 0951-7375

IS - 3

ER -